Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

O. Schnell, E. Standl, D. Catrinoiu, S. Genovese, N. Lalic, J. Skra, P. Valensi, A. Ceriello,

. 2016 ; 15 (-) : 33. [pub] 20160218

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu kongresy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000440

The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich ( http://www.dcvd.org).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000440
003      
CZ-PrNML
005      
20170116093345.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-016-0357-x $2 doi
024    7_
$a 10.1186/s12933-016-0357-x $2 doi
035    __
$a (PubMed)26892706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Schnell, Oliver $u Forschergruppe Diabetes e.V, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de.
245    10
$a Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group / $c O. Schnell, E. Standl, D. Catrinoiu, S. Genovese, N. Lalic, J. Skra, P. Valensi, A. Ceriello,
520    9_
$a The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have emerged in response to the FDA and the EMA Guidelines. The CVOT Summit stands as a novel conference setup, with the aim of serving as a reference meeting for all topics related to CVOTs in diabetes. Members of the steering committee of the D&CVD EASD Study Group constitute the backbone of the summit. It included presentations of key results on DPP-4 inhibitors, GLP-1-Analogues, SGLT-2 inhibitors, acarbose and insulins. Diabetologists' and cardiologists' perspective on the potential need of new study designs were also highlighted. Furthermore, panel discussions on the design of CVOTs on diabetes were included in the program. The D&CVD EASD Study Group will continue its activity. In-depth discussions and presentations of new CVOTs like LEADER, will be resumed at the 2nd CVOT on diabetes of the D&CVD EASD Study Group, which will be held from 20-22 October 2016 in Munich ( http://www.dcvd.org).
650    _2
$a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002318
650    _2
$a klinické zkoušky jako téma $x metody $7 D002986
650    _2
$a diabetes mellitus $x diagnóza $x farmakoterapie $x epidemiologie $7 D003920
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a rizikové faktory $7 D012307
655    _2
$a kongresy $7 D016423
700    1_
$a Standl, Eberhard $u Forschergruppe Diabetes e.V, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany. eberhard.standl@lrz.uni-muenchen.de.
700    1_
$a Catrinoiu, Doina $u Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd. No. 145, 900591, Constanta, Romania. dcatrinoiu@gmail.com.
700    1_
$a Genovese, Stefano $u Diabetes and Metabolic Disease Unit, IRCCS MultiMedica, Via Milanese 300, 20099, Sesto San Giovanni, MI, Italy. stefano.genovese@multimedica.it.
700    1_
$a Lalic, Nebojsa $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 13, Belgrade, 11000, Serbia. lalic.nm@gmail.com.
700    1_
$a Skra, Jan $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, 128 08, Prague 2, Czech Republic. jan.skrha@lf1.cuni.cz.
700    1_
$a Valensi, Paul $u Department of Endocrinology Diabetology Nutrition, Hôpital Jean VERDIER, Paris 13 University, CINFO, CRNH-IdF, Avenue du 14 Juillet, 93140, Bondy, France. paul.valensi@noos.fr.
700    1_
$a Ceriello, Antonio $u Institut d'Investigacions Biomèdiques August Pi I Sunyer-IDIBAPS, Mallorca, 183, 08036, Barcelona, Spain. ACERIELL@clinic.ub.es.
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 15, č. - (2016), s. 33
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26892706 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116093450 $b ABA008
999    __
$a ok $b bmc $g 1179580 $s 961007
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 15 $c - $d 33 $e 20160218 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace